Zalicus to Present at the 10th Annual World Pharma Conference
- Novel Calcium Channel Blockers Highlighted at Session on Targeting Pain with Novel Therapeutics -
- Advantages of Combination High-Throughput Screening Reviewed in Session on Cutting Edge Cell-Based Screening Technologies -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 2, 2011 - Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced two presentations at the 10th Annual World Pharma Conference June 7-9, 2011 in Philadelphia, PA. Terrance P. Snutch, Ph.D., FCAHS, FRSC, Chief Scientific Officer of Zalicus will present in a session highlighting novel ion channel therapeutics for the treatment of pain and Glenn Short, Ph.D., Director of Discovery Sciences at Zalicus will present in a session discussing cutting edge cell-based screening tools and the advantages of combination high-throughput screening.
In his talk entitled “Design and Preclinical Development of Novel T-Type and N-Type Calcium Channel Blockers for Pain Intervention”, Dr. Snutch will discuss preclinical efforts at Zalicus to rationally design and develop high affinity and state-dependent small molecule N-type and T-type blockers for pain intervention. Dr. Snutch will be presenting this work as part of a session on Targeting Pain with Novel Therapeutics, on Wednesday, June 8th at 11:20 a.m. ET.
Dr. Short will discuss the application of the next-generation Zalicus combination high throughput screening (cHTS) technology to correlate cancer cell line genotypic determinants with combination drug sensitivity to define multi-target drug combinations that synergistically induce genotype-specific cytotoxicity. Dr. Short's talk entitled “Using Combination Ultra High-Throughput Screening to Address Efficacious Drug Combinations to Responsive Tumor Genotypes” is part of a session on Novel Technologies for Cell-Based Screening, on Thursday, June 9th at 9:20 a.m. ET.
“As evidenced at this conference, our two innovative cell-based drug discovery platforms; the selective ion channel modulation platform, and the cHTS synergistic combination high throughput screening platform, continue to generate interesting leads and fuel the Zalicus pipeline going forward” said Mark H.N. Corrigan, MD, President and CEO of Zalicus Inc.
Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its product candidates, their potential and the plans for their clinical development, the Zalicus selective ion channel modulation technology, and related preclinical product candidates, Zalicus's combination drug discovery technology, cHTS, and its other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus may be identified by words like "believe," "expect," "may," "will," "should," "seek," “plan” or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the sale and marketing of Exalgo by Covidien, risks related to the development and regulatory approval of Zalicus's product candidates, including risks relating to formulation and clinical development of Synavive and Prednisporin, the unproven nature of the Zalicus drug discovery technologies, the ability of Covidien and Fovea/Sanofi Aventis to perform their obligations under their agreements with Zalicus, the ability of the Company or its collaboration partners to initiate and successfully complete clinical trials of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of Zalicus's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward-looking statements reflect management's current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
(c) 2011 Zalicus Inc. All rights reserved.
Posted: June 2011